PBPriya Bahri

Priya Bahri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Priya Bahri has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence

    by Mohamed A. Elhawary, Brian Edwards, Hadir Rostom, Shanthi N. Pal, Viola Macolic Sarinic, Priya Bahri, Deirdre McCarthy, Victoria Prudence Nambasa, Linda Härmark, Andrew Bate, et al.


  • Open Access

    Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations

    by Thomas Goedecke, Liana Martirosyan, Nathalie Gault, Karin Seifert, Daniel R. Morales, Priya Bahri, Valerie Strassmann, Martin Huber, Sabine Straus

    Purpose: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) launched a strategy to examine the public health impact of major regulatory interventions aimed at minimising risks of medicinal products. We conducted a lessons learnt analysis of impact studies completed between 2015 and 2023.Methods: We surveyed PRAC Sponsors and (Co‐)Rapporteurs involved in the evaluation of 12 impact studies (10 commissioned by EMA and 2 conducted collaboratively by Member States) to explore how these support regulatory decision‐making. Questions covered achievement of study objectives, risk minimisation effectiveness, added value for regulatory decision‐making, and recommendations for future impact studies. Themes were generated using thematic content analysis.Results: Survey responses from 15 PRAC Sponsors and (Co‐)Rapporteurs from 10 European Union Member States were included in the analysis. Among four cross‐sectional surveys and eight drug utilisation studies, 50% achieved all objectives, the other studies partially due to limitations. Two studies concluded that risk minimisation measures were overall effective, two were effective with variation across countries, two were partially effective and four studies showed limited effectiveness. Two studies were deemed inconclusive due to limitations. The reasons for the limited effectiveness of risk minimisation may be explored using mixed‐method approaches. Assessment of study feasibility and a priori discussion of effectiveness measurements is important.Conclusion: Despite limitations, impact research adds value to regulatory decision‐making by addressing knowledge gaps and providing additional information on unintended consequences of regulatory interventions. Our recommendations will help to improve planning, conducting and interpretating future impact studies.


  • Open Access

    The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System

    by Priya Bahri, Georgy Genov, Peter Arlett, Viola Macolić Šarinić, Evdokia Korakianiti, Alexis Nolte, Martin Huber, Sabine M. J. M. Straus

    This article reflects on the 2010 pharmacovigilance legislation of the European Union (EU). Its legislative aim of better patient and public health protection through new responsibilities for pharmaceutical companies and regulatory bodies is considered to have been achieved and is well supported by the good pharmacovigilance practices ‘EU-GVP’. For future progress, we set out a vision for high-quality pharmacovigilance in a world of ongoing medical, technological and social changes. To deliver this vision, four principles are proposed to guide actions for further progressing the EU pharmacovigilance system: synergistic interactions with healthcare systems; trustworthy evidence for regulatory decisions; adaptive process efficiency; and readiness for emergency situations (the ‘STAR principles’). Like a compass, these principles should guide actions for building capacity, technology and methods; improving regulatory processes; and expanding policies, frameworks and research agendas. Fit for the future, the EU system should achieve further improved outputs in terms of safe, effective and trusted use of medicines and positive health outcomes within patient-centred healthcare.


  • Open Access

    The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is Needed

    by Manal M. Younus, Mayada Alkhakany, Priya Bahri, Angela Caro, Hadir Rostom, Helen Byomire Ndagije, Mohamed A. Elhawary


  • Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

    by Priya Bahri, Geoffrey Bowring, Brian D. Edwards, Christopher Anton, Jeffrey K. Aronson, Angela Caro-Rojas, Bruce P. J. Hugman, Peter G. Mol, Gianluca Trifirò, Katarina Ilic, et al.


  • Open Access

    What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

    by Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans Hillege, Peter G. M. Mol

    Introduction Previous studies have found differences in the communication of safety issues among medicines regulatory agencies. Objectives To explore (1) to what extent regulators’ opinions regarding the need to communicate safety issues related to sodium-glucose cotransporter-2 (SGLT2) inhibitors might be influenced by their concern about the safety issue, and (2) whether regulators’ concerns might be influenced by certain characteristics of the safety issue or by the demographic and professional characteristics and attitudes of the regulators. Methods An online cross-sectional survey study with a rating-based conjoint analysis among clinical and pharmacovigilance assessors from the EU regulatory network was performed between April and June 2021. Regulators were invited by email, and participants were asked about their level of concern and their opinion regarding the need to communicate about 12 scenarios defined by four characteristics: adverse drug reaction, source of information, causality, and frequency. The outcomes for the first objective were to update the summary of product characteristics (SmPC; yes/no) and to send direct healthcare professional communications (DHPC; yes/no). The determinant was regulators’ level of concern (range 0–100%). The outcome of the second objective was regulators’ level of concern, and the determinants were the characteristics of the safety issue, demographic and professional characteristics, and attitudes of the regulators (beliefs about medicines and risk perception). Results A total of 222 regulators completed the survey (64% women; mean age 46 ± 10 years). Depending on the scenario, 54–94% and 25–74% of the participants would update the SmPC or send a DHPC, respectively. The participants’ level of concern influenced their opinions regarding the need to update the SmPC and send a DHPC (odds ratio (OR) 13.0; 95% confidence interval (CI) 7.8–21.7 and OR 13.6; 95% CI 9.5–19.2, respectively, for every 10% increase in the level of concern). All characteristics of the safety issue influenced the level of concern. Younger participants, women, and those working for Eastern European agencies had a higher level of concern than older participants, men, and those working in other regions. Beliefs about medicines and general risk perception also influenced their concern. Conclusions The opinion regarding the need to communicate safety issues was influenced by the concern of regulators. Regulators’ concern was influenced by the characteristics of the safety issue, demographic characteristics, and attitudes. Diverse groups of experts regarding such factors would ensure that various views are incorporated in risk communication decisions.


  • How do safety warnings on medicines affect prescribing?

    by Barbara Mintzes, Ellen Reynolds, Priya Bahri, Lucy T Perry, Alice L Bhasale, Richard L Morrow, Colin R Dormuth

    Many adverse effects of medicines only become known after approval, prompting regulatory agencies to issue post-market safety advisories to support safer care. Our team evaluated advisories issued ...


  • Open Access

    Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse

    by Priya Bahri, Antoine Pariente

    Introduction Input from patients and healthcare professionals to regulatory assessments is essential for benefit–risk management of medicines. How to best obtain input in different risk scenarios is uncertain. Objectives The objective of this study was to investigate whether the International Risk Governance Council (IRGC) Framework is applicable to pharmacovigilance and can guide selecting engagement mechanisms for optimising stakeholder input. Methods For proof-of-concept, classify ‘iconic’ cases of pharmacovigilance engagement at the European Medicines Agency (EMA) by IRGC risk scenario types and compare the engagement that happened with the engagement discourse recommended by the IRGC Framework for different risk scenarios. If the concept is proven, derive proposals for strengthening engagement. Results Six iconic cases were classified by risk scenario type at the respective time points when deciding on engagement: venous thromboembolism with combined hormonal contraceptives (complex risk); lipodystrophy with highly active antiretroviral therapy medicines, carcinogenicity with contaminated nelfinavir products (uncertain risks); teratogenicity with thalidomide, progressive multifocal leukoencephalopathy with natalizumab, teratogenicity and developmental disorders with valproate (ambiguous risks). The comparison of the engagement events with IRGC recommendations showed correspondence between the scope/outcomes of the events and the features of the recommended discourse. Conclusions The IRGC Framework appears applicable to pharmacovigilance. Proposals derived from the IRGC recommendations may be valuable for guiding regulators when selecting mechanisms for engagement with patients and healthcare professionals in given risk scenarios. The proposed decision guide aims at ensuring systematic and consistent engagement across regulatory assessments and providing for the most purposeful discourse, to effectively obtain real-world input for regulatory risk assessment, evaluation of risk minimisation measures and decision making.


  • Open Access

    Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines

    by Miriam Sturkenboom, Priya Bahri, Antonella Chiucchiuini, Tyra Grove Krause, Susan Hahné, Alena Khromava, Maarit Kokki, Piotr Kramarz, Xavier Kurz, Heidi J. Larson, et al.